According to the National Institute on Aging and Alzheimer’s Association (NIA-AA) research framework, AD-related biomarkers are mainly classified into three existing groups, including amyloid-β (Aβ) deposition, pathologic tau aggregation, and neurodegeneration [AT(N)] (Jack et al., 2018; Scheltens et al., 2021). This evidence concerns the gene MAPT and Alzheimer disease.